Navigation Links
Cardiome To Release Second Quarter Results And Hold Conference Call
Date:8/11/2008

ch forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology c
'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cardiome to Present at Bear Stearns Conference
2. Cardiome to Present at ThinkEquity Conference
3. Cardiome to Present at CIBC Conference
4. Cardiome To Release Third Quarter Results
5. Cardiome Initiates Phase 1 Study for GED-aPC
6. Cardiome Updates Guidance
7. Cardiome to Hold Investor Update Call
8. Cardiome And Astellas Announce Regulatory Update
9. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
10. Cardiome To Release 2007 Results
11. Cardiome To Release 2008 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... Let’s not lose focus of why people ... traffic magnets. Three out of 4 consumers choose to ... department, according to a Packaged Facts survey. Produce Managers ... to add more fruits and vegetables to their lifestyle. ... April 2. As featured in the Chase’s Calendar of ...
(Date:3/26/2015)... March 26, 2015 UC Davis will ... into the origins of schizophrenia: A Silvio O. Conte ... only 15 such centers in the United States. , ... grant from the National Institutes of Mental Health, which ... novel hypothesis that an origin of schizophrenia may be ...
(Date:3/26/2015)... York, New York (PRWEB) March 26, 2015 ... continue to move forward nationwide, with the issuance ... underway in Pennsylvania and Louisiana. According to an ... federal multidistrict litigation established for Xarelto injury claims ... Louisiana will now allow plaintiffs to file cases ...
(Date:3/26/2015)... DC (PRWEB) March 26, 2015 “The SWEET ... to make healthy options more available and help parents who ... penny tax is a reasonable approach to support public health, ... of this issue for the health of all families,” said ... for Hispanic Health on the introduction of the Sugar-Sweetened Beverage ...
(Date:3/26/2015)... CA (PRWEB) March 26, 2015 Dr. ... are proud to announce expanded offerings for Bay Area ... Francisco Dental Implant Center has long been a top-rated ... expanded its offerings to meet the strong demand by ... our reputation as a top-rated dental implant facility in ...
Breaking Medicine News(10 mins):Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 2Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 3Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 4Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 2Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 3Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act in 114th Congress 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3
... WASHINGTON, Oct. 4 Michael J. Fitzpatrick,executive director ... today,thanked Senator Pete Domenici (New Mexico) for his ... statement followed the senator,s,announcement of his intention to ... 35 years in the nation,s capital, Senator Pete ...
... Oct. 4 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ... lung cancer detection testing and other cancer diagnostic ... of,Southborough, Mass. to provide a range of clinical ... clinical programs. "Averion is a global clinical ...
... The Hartford Center for Geriatric Nursing Excellence in the ... Hartford centers in the nation, have been funded for ... have the most recent evidence-based guidelines for caring for ... Centers of Geriatric Nursing Excellence, which will form the ...
... National IPF Awareness Week on Capitol Hill Drives,Efforts ... SAN JOSE, Calif., Oct. 4 The ... success of its fifth,annual National IPF Awareness Week, ... about the critical need to fund new research ...
... N.J., Oct. 4 The following is a,statement regarding ... health information online:, It is encouraging that companies ... personal health record (PHR) products and systems,that people can ... more companies will follow suit. Having ready access to ...
... MedImmune, Inc. today announced results from two important studies ... (IDSA) 45th Annual Meeting adding to the body of ... a viral pathogen that produces annual outbreaks usually between ... in healthy children, it can prove to be a ...
Cached Medicine News:Health News:Biomoda and Averion International Announce Agreement for Clinical Services 2Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 2Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 3Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 4Health News:Statement Regarding Microsoft's Announcement of New Services to Help People Store Their Health Information Online 2Health News:Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results 2
(Date:3/26/2015)... British Columbia, March 26, 2015  OncoGenex Pharmaceuticals, ... summary of clinical developments and announced fourth quarter ... Clinical Developments and Anticipated Near-term MilestonesCustirsen ... Teva agreed to negotiate the termination of their ... of the final termination agreement are ongoing. ...
(Date:3/26/2015)... 2015 Over-the-counter healthcare costs can be ... a new survey of store brand over-the-counter products ... cold to diabetes, can offer significant savings for ... the Private Label Manufacturers Association, assembled a market ... those essential for treatment of pre-diabetes and diabetes. ...
(Date:3/26/2015)... PLEASANTON, Calif. , March 26, 2015  Desert ... the Nation five times , is the first ... System in its emergency department to help clinicians prevent ... in Victorville, Calif. , is a ... and bariatric patients.  Using the Leaf Patient Monitor in ...
Breaking Medicine Technology:OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Consumers can keep over-the-counter medicine affordable by using store brands 2Desert Valley Medical Center First to Use Leaf Healthcare Patient Wearable Technology in its ED as Part of Hospital-wide Deployment 2Desert Valley Medical Center First to Use Leaf Healthcare Patient Wearable Technology in its ED as Part of Hospital-wide Deployment 3
... , ATLANTA and STOCKHOLM , ... (1907-1986), inventor of the radiosurgical instrument that bears his ... (Solna, Sweden ), performed the world,s first ... location of the first Leksell Gamma Knife. Karolinska University ...
... April 23 Yesterday, T he Lancet ... once-daily human GLP-1 analog, Victoza® (liraglutide [rDNA] injection) with a DPP-4 ... reductions in A1C, fasting plasma glucose (FPG), and body weight than ... , , ...
Cached Medicine Technology:Karolinska University Hospital Acquires Leksell Gamma Knife Perfexion to Expand Radiosurgery Versatility, Efficiency in Brain Cancer Therapy 2Karolinska University Hospital Acquires Leksell Gamma Knife Perfexion to Expand Radiosurgery Versatility, Efficiency in Brain Cancer Therapy 3The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 2The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 3The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 4The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 5The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 6
Maddox Rod, long handle...
... Snellen chart remains to most popular ... of different optotypes can be displayed ... landolt Cs, tumbling Es and kaye ... can be shown and a range ...
Snellen 10' Eye Test Chart....
... The Accutome Ultrasound Advent Pachymeter exceeds ... elements: For ALK and other lamellar procedures, ... to 90 microns. High end range is ... general patient care. Newly designed 55 angle ...
Medicine Products: